International Journal of Molecular Sciences Review ELTD1—An Emerging Silent Actor in Cancer Drama Play Ani-Simona Sevastre 1,† , Iuliana M. Buzatu 2,†, Carina Baloi 2,†, Alexandru Oprita 2, Alexandra Dragoi 2, Ligia G. Tataranu 3, Oana Alexandru 4, Stefania Tudorache 5,* and Anica Dricu 2 1 Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Medicine and Pharmacy, 200349 Craiova, Romania;
[email protected] 2 Department of Biochemistry, Faculty of Medicine, University of Medicine and Pharmacy, 200349 Craiova, Romania;
[email protected] (I.M.B.);
[email protected] (C.B.);
[email protected] (A.O.);
[email protected] (A.D.);
[email protected] (A.D.) 3 Department of Neurosurgery, Bagdasar-Arseni Hospital, 041915 Bucharest, Romania;
[email protected] 4 Department of Neurology, Faculty of Medicine, University of Medicine and Pharmacy, 200349 Craiova, Romania;
[email protected] 5 Department of Obstetrics and Gynecology, Faculty of Medicine, University of Medicine and Pharmacy, 200349 Craiova, Romania * Correspondence:
[email protected] † These authors contributed equally. Abstract: The epidermal growth factor, latrophilin, and seven transmembrane domain–containing protein 1 (ELTD1), is a member of the G–protein coupled receptors (GPCRs) superfamily. Although discovered in 2001, ELTD1 has been investigated only by a few research groups, and important data about its role in normal and tumor cells is still missing. Even though its functions and structure are not yet fully understood, recent studies show that ELTD1 has a role in both physiological and Citation: Sevastre, A.-S.; Buzatu, pathological angiogenesis, and it appears to be a very important biomarker and a molecular target in I.M.; Baloi, C.; Oprita, A.; Dragoi, A.; cancer diseases.